The research conducted by Andrew D. Badley, M.D., focuses on virus-host interactions; in particular, on how viral proteins modify the host-immune response and on cell survival. This research covers the spectrum of basic science discovery, translational studies and novel clinical trials designed to apply discoveries into novel therapies for patients. At Mayo Clinic, Dr. Badley serves as director of the HIV Immunology Laboratory, associate chair of research in the Department of Internal Medicine, chair and professor of the Department on Molecular Medicine, and the director of the Office of Translation to Practice, whose mission is to advance scientific discoveries into products that improve patient care.
- Regulation of TNF-related apoptosis-inducing ligand (TRAIL) in the setting of HIV infection and cancer
- Impact of a novel splice variant of TRAIL called TRAILshort on TRAIL signaling
- Impact of HIV protease cleavage of host Casp8p41 on infected cell survival, and novel strategies to modify this pathway to cure HIV
Significance to patient care
Dr. Badley's long-term research goals are to develop novel strategies to cure HIV by eradicating HIV reservoirs, and to create novel immune-based therapies with applications in both virology and oncology.
- Named, H.H. Sheikh Khalifa bin Zayed Al Nahyan Professor of Infectious Diseases, 2018
- Recipient, Outstanding Investigator Award, Mayo Clinic, 2016
- Clinician Investigator Scientist, Mayo Clinic and Foundation, 2010
- Fellow, Infectious Diseases Society of America, 2008
- Recipient, Dalhousie Young Alumnus Award, Dalhousie University, 2006
- Fellow, American College of Physicians (FACP), 2005
- Elected member, American Society of Clinical Investigation, 2006
- Fellow, American College of Physicians, 2005
- Recipient, Clinical Scientist Award in Translational Research, Burroughs Wellcome Fund, 2005